Is SYRS or MO a better dividend investment in 2026?

SYRS currently yields 1000000.00% with a 5% 5-year dividend growth rate. MO yields 9.11% with 4.3% growth. The better choice depends on your goal: SYRS offers higher current income.

What is the dividend yield difference between SYRS and MO?

SYRS has a forward dividend yield of 1000000.00% ($2.00/share annually). MO yields 9.11% ($4.08/share annually). The yield gap is 999990.89 percentage points.

Home › Compare › SYRS vs MO

SYRS vs MO: Dividend Comparison 2026

SYRS yields 1000000.00% · MO yields 9.11%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 SYRS wins by $4.7683925249533696e+36M in total portfolio value

INVESTMENT

TIME HORIZON10 years

SYRS

● Live price

1000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.7683925249533696e+36M

Annual income

$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00

Full SYRS calculator →

Altria Group Inc.

● Live price

9.11%

Share price

$44.80

Annual div

$4.08

5Y div CAGR

4.3%

Payout ratio

78%

After 10 yrs · $10,000 · DRIP

Portfolio value

$27.7K

Annual income

$4,052.72

Full MO calculator →

Portfolio growth — SYRS vs MO

📍 SYRS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	SYRS	MO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, SYRS + MO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

SYRS pays

MO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SYRS

Annual income on $10K today (after 15% tax)

$85,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr

Annual income on $10K today (after 15% tax)

$774.11/yr

After 10yr DRIP, annual income (after tax)

$3,444.81/yr

At 15% tax rate, SYRS beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SYRS + MO for your $10,000?

SYRS: 50%MO: 50%

100% MO50/50100% SYRS

Portfolio after 10yr

$2.3841962624766848e+36M

Annual income

$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr

Blended yield

99.98%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

SYRS

Analyst Ratings

Buy

Hold

Consensus: Hold

Price Target

$16.67

+8334900.0% upside vs current

Range: $5.00 — $30.00

Altman Z

-15.5

Piotroski

0/9

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$61.25

+36.7% upside vs current

Range: $47.00 — $68.00

Altman Z

3.2

Piotroski

7/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SYRS buys

MO buys

No recent congressional trades found for SYRS or MO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricSYRSMO

Forward yield	1000000.00% ✓	9.11%
Annual dividend / share	$2.00	$4.08 ✓
Payout ratio	50% ✓	78%
1-year div growth	0%	4.1% ✓
5-year div CAGR	0%	4.3% ✓
Portfolio after 10y	$4.7683925249533696e+36M	$27.7K ✓
Annual income after 10y	$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00 ✓	$4,052.72
Total dividends collected	$4.7683311610149396e+36M	$20.9K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Consumer Staples
Analyst consensus	Hold	Buy
Analyst price target	$16.67	$61.25 ✓

Year-by-year: SYRS vs MO ($10,000, DRIP)

Year	SYRS Portfolio	SYRS Income/yr	MO Portfolio	MO Income/yr	Gap
1← crossover	$100,010,700	$100,000,000.00	$10,740	$949.88	+$100.00M → SYRS
2	$934,786,450,701	$934,679,439,252.34	$11,601	$1,086.84	+$934786.44M → SYRS
3	$8,165,787,108,578,292	$8,164,786,887,076,042.00	$12,608	$1,250.75	+$8165787108.57M → SYRS
4	$66,665,884,190,957,650,000	$66,657,146,798,751,470,000.00	$13,792	$1,448.20	+$66665884190957.63M → SYRS
5	$508,662,171,058,048,100,000,000	$508,590,838,561,963,700,000,000.00	$15,190	$1,687.69	+$508662171058048128.00M → SYRS
6	$3,627,235,248,428,489,700,000,000,000	$3,626,690,979,905,457,600,000,000,000.00	$16,851	$1,980.28	+$3.62723524842849e+21M → SYRS
7	$24,173,681,159,150,610,000,000,000,000,000	$24,169,800,017,434,790,000,000,000,000,000.00	$18,838	$2,340.48	+$2.417368115915061e+25M → SYRS
8	$150,567,402,861,454,640,000,000,000,000,000,000	$150,541,537,022,614,370,000,000,000,000,000,000.00	$21,230	$2,787.44	+$1.5056740286145463e+29M → SYRS
9	$876,477,100,281,847,600,000,000,000,000,000,000,000	$876,315,993,160,785,800,000,000,000,000,000,000,000.00	$24,130	$3,346.72	+$8.764771002818475e+32M → SYRS
10	$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000	$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00	$27,676	$4,052.72	+$4.7683925249533696e+36M → SYRS

SYRS vs MO: Complete Analysis 2026

SYRS — Stock

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Full SYRS Calculator →

MO — Consumer Staples

Altria is a Dividend King with 54+ consecutive years of dividend increases — one of the longest streaks in American corporate history. While cigarette volumes decline, pricing power and new product categories (oral nicotine pouches via NJOY) support cash flows. The near-9% yield is among the highest in the S&P 500.

Full MO Calculator →

📬

Get this SYRS vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SYRS vs SCHD SYRS vs JEPI SYRS vs O SYRS vs KO SYRS vs MAIN SYRS vs PM SYRS vs BTI SYRS vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.